Kornimate/medical-research-clean huggingface dataset:
a comparison of injection pain of propofol during endoscopy : lct propofol vs mct/lct propofol

Conditions: Pain; Complication of Injection

Summary: the purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by long chain triglyceride propofol versus medium/long chain combinated triglyceride propofol on endoscopy.


Eligibility criteria:
inclusion criteria: * age \>15 yrs * asa (american society of anesthesiologists risk class iii-iv)i-ii * patients undergoing to gastroscopy exclusion criteria: * significant systemic disease (american society of anesthesiologists risk class iii-iv) * history of allergic reactions to any of the study drugs * chronic use of opioid analgesics * psychiatric disorder * arrythmia * pregnancy * age \<18 yrs
correlation analysis between rotator cuff tear and the superior migration of humeral head

Conditions: Rotator Cuff Tear

Summary: to evaluate the association between rotator cuff tear and the proximal migration of humeral head

in this research, 60 patients with unilateral rotator cuff tear in peking university people's hospital in 2018 are planned to be recruited .they will receive magnetic resonance imaging(mri) and x-ray of the painful shoulder before enrollment in this study, the duration between the two examinations was no longer than 1 week, also there is no past history of surgery in the selected shoulders. there is no other exclusion criteria. upward migration index(umi) is the ratio between the distance of humeral head center to the lower surface of acromion, and the radius of humeral head circle. it can help to minimize the effect of anatomy difference and imaging magnification, compared with the traditional acromiohumeral distance(ahd). then we use the spearman correlation analysis to evaluate the relationship between umi and fatty degeneration, rotator cuff tear size and the thickness of ruptured supraspinatus tendon from x-ray and mri.

Eligibility criteria:
inclusion criteria: * patient receive magnetic resonance imaging half year before enrollment, showing supraspinatus tear * patient receive x-ray half year before enrollment * the duration between the two examinations was no longer than 1 week * no past history of surgery in the selected shoulders exclusion criteria: * patients who cannot receive mri.

Keywords: rotator cuff tear magnetic resonance imaging humeral migration
laparoscopic assisted versus open resection for colorectal carcinoma

Conditions: Colorectal Carcinoma

Summary: the aim of the investigators' randomized trial is to compare the short-term clinical outcome and survival between laparoscopic-assisted and open resection of colorectal carcinoma.

since the introduction of laparoscopic cholecystectomy in 1987, laparoscopic surgery has been attempted and applied to many surgical operations. surgeons in hong kong began to perform laparoscopic surgery for colorectal carcinoma in early 1992. early reports of laparoscopic surgery for colorectal carcinoma from hong kong and worldwide suggested better short-term clinical outcomes when compared with open surgery, but there were concerns over port site metastases and adequacy of long-term oncological clearance. besides, only a few randomized trials thus far have compared laparoscopic-assisted and open surgery for rectal carcinoma. the aim of our randomized trial is to compare the short-term clinical outcome and survival between laparoscopic-assisted and open resection of colonic and rectal carcinoma. patients will undergo different types of surgery according to the location of the tumors: right or extended right hemicolectomy for cecal, ascending colon, or hepatic flexure tumors; left hemicolectomy for descending colon tumors; sigmoid colectomy for sigmoid colon tumors; anterior resection for rectosigmoid or upper rectal tumors; low anterior resection with total mesorectal excision for mid- and low rectal tumors; abdominoperineal resection for very low rectal tumors. patients will be randomly allocated to laparoscopic assisted or conventional open surgery. short-term clinical outcome and long-term survival data will be prospectively recorded and compared between the two treatment arms.

Eligibility criteria:
inclusion criteria: * patients diagnosed to have colorectal carcinoma at all locations except transverse colon * informed consent available exclusion criteria: * patients with tumor \>6 cm in size, or with tumor infiltration to adjacent organs on imagings * patients with previous abdominal surgery near the region of the colorectal surgery * patients with intestinal obstruction or perforation * patients with recurrent disease * patients with synchronous colorectal carcinoma

Keywords: colorectal carcinoma rectal carcinoma laparoscopy laparoscopic surgery open surgery randomized trial
enhanced device programming to reduce therapies and improve quality of life in implantable cardioverter defibrillator (icd) patients

Conditions: Cardiac Arrhythmias

Summary: the purpose of this study is to determine whether enhanced device programming to reduce therapies (i.e. anti tachycardia pacing (atp) episodes and shocks (both appropriate and inappropriate)) is safe for patients implanted with an implantable cardioverter-defibrillator (icd). the secondary objective is to examine the impact of enhanced programming on (i) atps and shocks (both appropriate and inappropriate) and (ii) quality of life and distress.

icd therapy has become the first-line treatment for the prevention of sudden cardiac death both as primary and secondary prevention due to its proven survival benefits as compared to anti-arrhythmic drugs. however, icd therapy is associated with a number of complications and shocks that may impair patient quality of life and well being but also influence mortality. hence, reduction of icd shocks by means of alternative programming of the device is paramount for improving patient-centered outcomes and mortality. the enhanced-icd study will be a prospective, single-arm safety monitoring study. all patients will receive enhanced programming. furthermore, patients will be asked to complete a set of standardized and validated self-report questionnaires prior to icd implantation, at 3-, 6-, and 12 months post implantation.

Eligibility criteria:
inclusion criteria: * a primary or secondary prophylactic indication for icd therapy according to the current european guidelines * implanted with a medtronic protectatm icd/crt-d device or any future ce-approved and market-released medtronic icd/crt-d devices with smartshock technology * between 18-80 years of age * speaking and understanding dutch * providing written informed consent exclusion criteria: * a life expectancy less than 1 year * a history of psychiatric illness other than affective/anxiety disorders * on the waiting list for heart transplantation * insufficient knowledge of the dutch language

Keywords: cardiac arrhythmias implantable cardioverter-defibrillator patient safety quality of life
validation of hemorrhoidal bleeding score

Conditions: Hemorrhoid Bleeding

Summary: the principal manifestation of hemorrhoidal disease is bleeding; however the severity evaluation is today based on prolapsus (goligher classification) and bleeding factor is not included. even if there was some rare score including bleeding in literature , none of them were validated. the aim of the study is first validation of bleeding score .


Eligibility criteria:
inclusion criteria: * age\>18 years * consulting for hemorroidal bleeding * accept to participate exclusion criteria: * paraplegic or hemiplegic patient * misunderstanding of the french language
fat reduction induced by magnetic device - ultrasonographic evaluation

Conditions: Fat Burn

Summary: the study is a prospective multi-center open-label single-arm study. the subjects will be enrolled and assigned into a single study group. subjects will be required to complete four (4) treatment visits and four follow-up visits, 1 month, 3, 6 and 12 months after the final treatment. at the baseline visit photographs of the abdomen will be taken. in addition, adipose/muscle layer thickness will be measured with the ultrasound and the subject's weight will be recorded. in addition, at the last therapy visit, subjects will receive subject satisfaction and therapy comfort questionnaires to fill in. safety measures will include documentation of adverse events (ae) including subject's experience of pain or discomfort after the procedure. following each treatment administration and at the follow-up visits, subjects will be checked for immediate post-procedure adverse event assessment. post-procedure evaluation (follow-up visits) will be conducted 1 month, 3, 6 and 12 months after the final treatment. an ultrasound imaging and weight measure will be conducted. also, subject's satisfaction will be noted. during the first (1 month), third (6 months) and last (12 months) follow-up visits, photographs of abdomen will be taken.


Eligibility criteria:
inclusion criteria: * adult subjects of both genders with unwanted abdominal fat and expressing interest in treatment * age ≥ 22 years * voluntarily signed informed consent form * bmi ≤ 30 kg/m2 exclusion criteria: * cardiac pacemakers * electronic implants * pulmonary insufficiency * metal implants * drug pumps * haemorrhagic conditions * anticoagulation therapy * heart disorders * malignant tumor * fever * pregnancy * breastfeeding * following recent surgical procedures when muscle contraction may disrupt the healing process * application over menstruating uterus * application over areas of the skin which lack normal sensation * scars, open lesions and wounds at the treatment area * unrepaired abdominal hernia

Keywords: abdominal fat
growth, allergy and neurodevelopment in infants on hydrolysed formula

Conditions: Infant Formula

Summary: breastfeeding is the recommended diet for all infants during the first half of infancy and is associated with numerous health benefits. however, when breastfeeding is not possible, an infant formula is the only nutritive alternative. formula-fed infants have a different growth pattern compared to breastfed infants. studies have shown that the higher protein content in infant formula compared to breastmilk results in a more rapid weight gain and an increased risk of overweight and obesity in childhood. for this reason, both quantity and quality of protein in infant formulae have been optimized during the last decade, to better meet the needs of infants and to support growth close to that of breastfed infants. protein hydrolysis, a common modification of infant formulae, has originally been developed for treatment of cow's milk protein allergy. certain hydrolysed formulae have been suggested to prevent atopic eczema when given to infants with a family history of allergic disease but as of yet, the allergy preventive effect in infants without increased risk of allergic disease has been little studied. partially hydrolysed infant formulae have also been suggested to reduce common functional gastrointestinal symptoms in infants. new protein hydrolysates are continually developed for use in infant formulae, with the aim of reducing allergenicity, while ensuring optimal growth and development of infants. it is important to study the effects on growth and health outcomes in infants who are fed formulae based on these newly developed hydrolysates as compared to those fed standard intact protein formulae or breastmilk. the overall aims of the current study are to evaluate the effects of two new hydrolysates on growth, immunological biomarkers, neurodevelopment, protein metabolism and gut microbiota in a randomized, controlled clinical trial of healthy infants. in compliance with european food safety authority (efsa) regulations for novel infant formulas based on hydrolysed protein, the primary outcome is change in weight standard deviation score (sds) from baseline until 5 months of age.


Eligibility criteria:
inclusion criteria: * healthy infants born at term * birth weight 2500 to 4500 gram * either exclusive breast-feeding (reference group) or exclusive formula-feeding (intervention and control group) exclusion criteria: * suspected or verified food allergy * suspected or verified infant colic

Keywords: infant nutrition food hypersensitivity dermatitis, atopic protein hydrolysates spectroscopy, near-infrared
efficacy and safety of mp-424/peginterferon alfa-2b/ribavirin combination in treatment-naïve patients with chronic hepatitis c

Conditions: Hepatitis C

Summary: this study will evaluate the efficacy and safety of mp-424 with peginterferon alfa-2b (peg-ifn) and ribavirin (rbv) in treatment-naïve patients with (genotype 1) hepatitis c.


Eligibility criteria:
inclusion criteria: * genotype 1, chronic hepatitis c * treatment-naïve (patient who has received no previous interferon based treatment for hepatitis c) * able and willing to follow contraception requirements exclusion criteria: * cirrhosis of the liver or hepatic failure * hepatitis b surface antigen-positive or hiv antibodies-positive * history of, or concurrent hepatocellular carcinoma * history of, or concurrent depression, schizophrenia; or suicide attempt in the past * pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant

Keywords: chronic hepatitis c protease inhibitor telaprevir peginterferon alfa-2b ribavirin
external pancreatic stent in pancreaticojejunostomy

Conditions: Pancreatic Fistula

Summary: pancreatic fistula is one of the most serious complication after pancreatoduodenectomy. to reduce pancreatic fistula, many authors recommend pancreatic stent in pancreatojejunostomy. the purpose of this study is to determine which is the best method in preventing pancreatic fistula and to investigate its long term clinical outcomes.

the role of external pancreatic duct drainage in managing patients with a soft pancreas is particularly important, as these patients are at a heightened risk of developing postoperative complications. by providing an external route for pancreatic secretions, external pancreatic duct drainage may help to reduce the enzymatic activity at the anastomosis site and promote better healing. in addition to reducing the incidence of post operative pancreatic fistula, external pancreatic duct drainage may have other potential benefits, such as decreasing the length of hospital stay, reducing the need for additional interventions, and improving overall patient quality of life. however, these potential benefits must be weighed against the risks and drawbacks of external pancreatic duct drainage, including the potential for stent-related complications and the need for an additional procedure to remove the stent. •after being informed about the study and potential risks, all patients giving written consent. patients who meet the eligibility requirements will be randomized in a 1:1 ratio to external pancreatic drainage group and no external pancreatic drainage group.

Eligibility criteria:
inclusion criteria: * patients undergoing pancreaticoduodenectomy (whipple procedure) for various indications (e.g., pancreatic cancer, ampullary cancer, etc.). * patients with a confirmed soft pancreas texture, as determined intraoperatively by the surgeon. exclusion criteria: * patients with a hard or fibrotic pancreas, as determined intraoperatively by the surgeon. * patients with severe uncontrolled comorbidities (e.g., uncontrolled diabetes, severe cardiovascular disease, renal failure). * pregnancy or lactation.
olanzapine for nausea after surgery

Conditions: Postoperative Nausea and Vomiting

Summary: ambulatory surgery is occurring with rapidly increasing frequency as surgical and anesthetic techniques have improved and pressure to reduce health-care costs has increased. while there are many benefits to recovering from surgery within the home, a significant disadvantage is the lack of rapid access to a healthcare provider when postoperative complications occur. postoperative nausea and vomiting (ponv) are common after surgery and anesthesia, and recent studies have demonstrated a high incidence of post-discharge nausea and vomiting (pdnv) after ambulatory surgery, particularly in high-risk groups (female gender, age less than 50 years, history of ponv, opioid administration in the post-anesthesia care unit (pacu), and nausea in the pacu). current practices known to reduce the risk of postoperative nausea and vomiting in the pacu, such as the avoidance of volatile anesthetics and the use of intraoperative ondansetron and steroids, have little effect on the risk of delayed pdnv. novel strategies to prevent pdnv are needed. orally administered olanzapine, which has been shown to decrease the incidence of chemotherapy-induced nausea and vomiting, demonstrates promise as a novel strategy for preventing pdnv. it has a long half-life, allowing for a single dose to be administered preoperatively. this study will evaluate whether there is a difference in the incidence and severity of pdnv between patients who receive oral olanzapine versus placebo prior to general anesthesia for ambulatory surgery.


Eligibility criteria:
inclusion criteria: * adults age ≥ 18 and ≤ 50 years old * patient scheduled to undergo ambulatory surgery under general anesthesia * willing and able to provide informed consent exclusion criteria: * unable to swallow pills * current use of typical or atypical anti-psychotic medications * history of allergy to olanzapine * pregnancy/lactation (subjects of child-bearing potential will have a urine pregnancy test performed the day of surgery) * history of qtc \> 450ms or torsades de pointes * current use of antihypertensive medication * diabetes mellitus * clinically significant cardiovascular disease defined as follows: 1. myocardial infarction or unstable angina within 6 months prior to the day of planned surgery. 2. history of serious ventricular arrhythmia (i.e.: ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled on anti-arrhythmic medication. 3. new york heart association (nyha) class ii or higher congestive heart failure. * postural hypotension or vasovagal syncope within 6 months of planned surgery. * hypotension on day of surgery, defined as a systolic blood pressure \< 90mm hg or a diastolic pressure \< 60mm hg. * seizure disorder * clinically active prolactinoma * hepatic disease * poorly controlled diabetes * pre-operative blood glucose \> 250 mg/dl * narrow angle glaucoma * parkinson's disease * lewy body dementia

Keywords: nausea vomiting
nasal muco-ciliary clearance study with and without salt inhalation

Conditions: Obstructive Airway Diseases

Summary: investigating nasal muco-ciliary clearance by scintigraphy

the velocity and the retention of the nasal muco-ciliary clearance is going to be investigated with a salt particle inhaler and a placebo by the method nasal scintigraphy. the hypotheses is that nasal inhalation of salt particles enhance the nasal mucociliary clearance.

Eligibility criteria:
inclusion criteria: * copd patients (all severities in chronic, stable condition) * asthma patients (in stable condition without acute asthma symptoms) * healthy subjects, incl. smokers (no chronic nasal, upper or lower respiratory diseases) exclusion criteria: * age under 18 years * upper respiratory tract infection / cold within the last 3 weeks and at least 3 weeks must pass from the person has become well to the examination * allergic / non-allergic rhinitis (hay fever) * chronic sinusitis * acute respiratory tract infection in antibiotic therapy * applied salt inhalation within the past month * pregnant or breastfeeding women * nuclear medical examination within the past month * cannot taste saccharin
effect of short-term simulated altitude exposure on cardiopulmonary functional capacity

Conditions: Hypoxia

Summary: to determine if exposure of older volunteers, age 50-70y, who are healthy, but not physically active, to 7 days of mild hypoxia (15% oxygen, equivalent 2440m) will improve cardiopulmonary functional capacity.

background there is an urgent need to reduce morbidity and mortality following major surgery. bodily demands for oxygen increase after major surgery, and postoperative outcomes can be predicted by quantifying the body's ability to meet increased mitochondrial demand for oxygen using cardiopulmonary exercise testing (cpet). design this is a preliminary, physiological study to establish the baseline relationship between mild hypoxia exposure and cardiopulmonary function. this study will begin to examine the feasibility and potential for achieving risk modification through low-oxygen (hypoxic) conditioning, in which a safe and convenient "dose" of mild hypoxia is used to improve cpet derived variables that predict mortality following surgery. the study will use a randomised, double blind, sham-controlled, crossover design. after a baseline cpet test, participants will be exposed to 7 days of either mildly hypoxic or normoxic air. a follow up cpet test will then be used to determine if cardiopulmonary functional capacity increased after exposure. after a two week washout period, participants will return for a second 7-day session where the alternate exposure will be given. a final follow-up cpet test will then be performed.

Eligibility criteria:
inclusion criteria: * healthy male and female individuals aged 50-70 years with sedentary lifestyles. exclusion criteria: * known intolerance to altitude identified by the participant's clinical examination, history and pre-altitude screening completed by the research clinician. * non-availability and/or suitability to complete the required residential period within the altitude centre.

Keywords: hypoxic conditioning cardio pulmonary exercise testing
n-acetylcysteine in patients with sickle cell disease

Conditions: Sickle Cell Disease

Summary: the primary aim of this study is to evaluate the effect of the drug n-acetylcysteine on the frequency of pain in daily life in patients with sickle cell disease (scd). pain is an invalidating hallmark of this disease and has a considerable impact on the quality of life of patients and the medical health care system. oxidative stress is hypothesized to play a central role in its pathophysiology. in pilot studies the administration of n-acetylcysteine (nac) resulted in a reduction of oxidative stress. moreover, administration of nac seemed to decrease hospitalization for painful crises in a small pilot study in patients with scd. this study will be performed as a multicenter, randomized, controlled trial where patients will be treated with either nac or placebo for a period of 6 months. the investigators expect that nac can reduce the frequency of pain in patients with scd, thereby improving their quality of life and participation in society.


Eligibility criteria:
inclusion criteria: * age 12 years or older * sickle cell disease, either homozygous sickle cell disease (hbss), compound heterozygous sickle cell disease (hbsc), hbsβ0 or hbsβ+ thalassemia * history of at least 1.0 painful crisis per year in the past 3 years (visit to medical facility is not required) exclusion criteria: * chronic blood transfusion or transfusion in the preceding 3 months * painful crisis in the last 4 weeks (with respect to the moment of inclusion) * pregnancy, breast feeding or the desire to get pregnant in the following 7 months * known active gastric/duodenal ulcers * hydroxycarbamide (hc) treatment with unstable dose in the last 3 months or started on hc shorter then 6 months prior to study * known poor compliance in earlier trials regarding the completion of pain diaries * insufficient compliance in run-in period * known hypersensitivity to acetylcysteine or one of the other components of the study medication * use of pain medication for sickle-cell related pains on more than 15 days per month in the past 6 months ('chronic pain').

Keywords: sickle cell disease sickle cell anemia pain n-acetylcysteine acetylcysteine oxidative stress